Select Page
Abstract Number 629: Loss of 5q Drives Evolution to Aneuploidy in an iPSC Model of Complex Karyotype AML

Abstract Number 598: HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo EspaÁ±ol De Trasplante y Terapia Celular (GETH-TC)

BackgroundIn 2022, the European LeukemiaNet (ELN) updated its guidelines for risk allocation in acute myeloid leukemia (AML) patients (Döhner H et al., Blood 2022). Subsequently, a few studies validated externally the prognostic value of this new classification in...
Abstract Number 629: Loss of 5q Drives Evolution to Aneuploidy in an iPSC Model of Complex Karyotype AML

Abstract Number 447: Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Introduction: Acute myeloid leukemia (AML) has been considered by many to be an oncologic emergency often leading to hospital admission for expeditious evaluation and treatment. Previous studies reported that time from diagnosis to treatment (TDT) does not impact...